# First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

> **NCT04993443** · PHASE1 · TERMINATED · sponsor: **Syneos Health** · enrollment: 40 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** LQ036
- **OTHER:** Matching Placebo

## Key facts

- **NCT ID:** NCT04993443
- **Lead sponsor:** Syneos Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-06
- **Primary completion:** 2023-03-02
- **Final completion:** 2023-03-09
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Copmeletion of Part A SAD cohorts, sponsor cancelled Part B-D cohorts
- **Last updated:** 2023-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993443, "First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04993443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*